Positive News SentimentPositive NewsNASDAQ:GLUE Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis $7.74 +0.11 (+1.44%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$7.64 -0.11 (-1.36%) As of 10/3/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Monte Rosa Therapeutics Stock (NASDAQ:GLUE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GLUE alerts:Sign Up Key Stats Today's Range$7.59▼$7.8650-Day Range$4.19▼$7.7452-Week Range$3.50▼$12.40Volume586,137 shsAverage Volume2.52 million shsMarket Capitalization$478.01 millionP/E Ratio21.50Dividend YieldN/APrice Target$15.33Consensus RatingHold Company Overview Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden. The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience. In immuno-oncology, Monte Rosa applies its platform to better understand tumor microenvironments and to design molecules that modulate immune cell activity. In neuroscience, the company focuses on identifying targets implicated in neurodegenerative and neuroinflammatory disorders. Through this dual therapeutic focus, Monte Rosa seeks to advance candidates from early discovery through lead optimization and into partnerships or further development stages. Monte Rosa operates at the intersection of technology and biology, collaborating with academic institutions and industry partners to validate its discoveries and expand its library of therapeutic assets. The company is led by a team of experienced executives and scientists with backgrounds in genomics, AI, drug development and venture financing. While primarily based in the United States, Monte Rosa’s platform and partnerships enable it to engage with global research networks and to pursue programs with worldwide impact.AI Generated. May Contain Errors. Read More Monte Rosa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreGLUE MarketRank™: Monte Rosa Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 448th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMonte Rosa Therapeutics has a consensus price target of $15.33, representing about 98.1% upside from its current price of $7.74.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Monte Rosa Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($1.49) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is 21.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 222.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is 21.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 65.27.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Monte Rosa Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.84% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.84% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous month News and Social Media3.7 / 5News SentimentN/A News SentimentMonte Rosa Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for GLUE on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows3 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.50% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions79.96% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Monte Rosa Therapeutics' insider trading history. Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLUE Stock News HeadlinesPallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth ProspectsSeptember 30, 2025 | insidermonkey.comMonte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POCSeptember 18, 2025 | seekingalpha.comURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash before 2025 ends. | StockEarnings (Ad)Monte Rosa Therapeutics And The Promise Of Molecular Glue DegradersSeptember 16, 2025 | seekingalpha.comMonte Rosa stock rises after pact with NovartisSeptember 15, 2025 | msn.comNovartis returns to Monte Rosa for second time in a year with $5.7bn dealSeptember 15, 2025 | finance.yahoo.comMonte Rosa stock soars after $120M Novartis collaboration dealSeptember 15, 2025 | ca.investing.comMonte Rosa Therapeutics Shares Soar on Drug Partnership with NovartisSeptember 15, 2025 | marketwatch.comSee More Headlines GLUE Stock Analysis - Frequently Asked Questions How have GLUE shares performed this year? Monte Rosa Therapeutics' stock was trading at $6.94 at the beginning of 2025. Since then, GLUE stock has increased by 11.5% and is now trading at $7.74. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its earnings results on Thursday, August, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.16. The firm earned $23.19 million during the quarter, compared to analyst estimates of $7.23 million. Monte Rosa Therapeutics had a trailing twelve-month return on equity of 9.95% and a net margin of 13.58%. When did Monte Rosa Therapeutics IPO? Monte Rosa Therapeutics (GLUE) raised $211 million in an initial public offering on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Monte Rosa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Monte Rosa Therapeutics investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/07/2025Today10/05/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLUE CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees90Year Founded2018Price Target and Rating Average Price Target for Monte Rosa Therapeutics$15.33 High Price Target$19.00 Low Price Target$10.00 Potential Upside/Downside+98.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio21.50 Forward P/E RatioN/A P/E GrowthN/ANet Income-$72.70 million Net Margins13.58% Pretax Margin15.97% Return on Equity9.95% Return on Assets6.42% Debt Debt-to-Equity RatioN/A Current Ratio7.16 Quick Ratio7.16 Sales & Book Value Annual Sales$177.99 million Price / Sales2.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book2.13Miscellaneous Outstanding Shares61,759,000Free Float57,745,000Market Cap$478.01 million OptionableOptionable Beta1.54 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:GLUE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.